secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001104659-26-057945
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio appoints Dr. Elizabeth Stoner to board, replaces Eef Schimmelpennink
-------------------------------------------------------------------------

- Dr. Stoner appointed as Class II director and Compensation Committee member, effective May 7, 2026.
- She brings 35+ years pharma R&D experience; currently Entrepreneur Partner at MPM BioImpact.
- Eef Schimmelpennink resigned immediately; departure not due to any disagreement with the Company.
- Standard non-employee director compensation: $40k annual board fee, $7.5k committee fee, option grant.
- CEO cites upcoming first human clinical trial for obesity and pulmonary hypertension therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926057945/0001104659-26-057945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926057945/ibio-20260507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-057945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer